Drug Profile

Zeleciment Basivarsen - Dyne Therapeutics

Alternative Names: DYNE-101; z-basivarsen

Latest Information Update: 10 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dyne Therapeutics
Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates; Immunoglobulin fragments
Mechanism of Action Gene silencing; Myotonin protein kinase expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myotonic dystrophy
New Molecular Entity Yes

Highest Development Phases

Phase III Myotonic dystrophy

Most Recent Events

29 Sep 2026 Efficacy and adverse events data from a phase I/II ACHIEVE trial in Myotonic dystrophy released by Dyne Therapeutics
03 Jun 2026 Dyne Therapeutics announces intention to launch DYNE 101 for Myotonic dystrophy in the US in H1 2028, assuming Priority Review
03 Jun 2026 Dyne Therapeutics announces intention to pursue approval pathways outside of the US for z-basivarsen in Myotonic dystrophy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com